BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Denosumab (Xgeva) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Denosumab (Xgeva)\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06749886-11057@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Denosumab (Xgeva): Phase 2 readout est. (NCT06749886)
DESCRIPTION:Denosumab (Xgeva)\, phase 2\, Non-Small Cell Lung Cancer.\nStud
 y: An Exploratory Study of Tislelizumab in Combination with Chemotherapy i
 n Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC i
 n the Second-line Setting\nEstimated primary completion: 30 November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-xgeva#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513624-11057@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Denosumab (Xgeva): Phase 1 readout est. (NCT06513624)
DESCRIPTION:Denosumab (Xgeva)\, phase 1.\nStudy: ETC-159 In Combination Wit
 h Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/denosumab-xgeva#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06513624
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04711109-11057@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Denosumab (Xgeva): Phase 3 readout est. (NCT04711109)
DESCRIPTION:Denosumab (Xgeva)\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Studying the Effect of Denosumab on Preventing Breast Cancer in
  Women With a BRCA1 Germline Mutation\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-xgeva
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047
 11109
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05966064-11057@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Denosumab (Xgeva): Phase 4 readout est. (NCT05966064)
DESCRIPTION:Denosumab (Xgeva)\, phase 4.\nStudy: DEnosumab for the Treatmen
 t of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/denosumab-xgeva#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05966064
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04586660-11057@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280307
DTEND;VALUE=DATE:20280308
SUMMARY:Denosumab (Xgeva): Phase 4 readout est. (NCT04586660)
DESCRIPTION:Denosumab (Xgeva)\, phase 4.\nStudy: Study of XGEVA® (Denosuma
 b) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tum
 or of the Bone\nEstimated primary completion: 7 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04586660
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
